Table 3 Ovicidal activity of BZDs on an ABZ-susceptible isolate of Fasciola hepatica at a concentration of 10 µM along with cytotoxicity values on HepG2 cells and toxicity assays carried out with organoids
From: New benzimidazole derivative compounds with in vitro fasciolicidal properties
Compound identification | % Ovicidal activity | CC50 | % Viability in organoids | % Viability in organoids |
|---|---|---|---|---|
10 µM | Hep-G2 | 25 µM | 50 µM | |
BZD04 | 64.27 ± 10.16 | 10.78 µM | 21.10% | 10.50% |
BZD08 | 55.33 ± 05.81 |  > 50 µM | 69.30% | 47.30% |
BZD20 | 24.59 ± 05.71 | – | – | – |
BZD27 | 44.65 ± 07.46 | 20.29 µM | 54.10% | 49.70% |
BZD30 | 52.41 ± 01.02 |  > 50 µM | 62.50% | 54.00% |
BZD31 | 99.58 ± 00.26 |  > 50 µM | 60.50% | 52.40% |
BZD32 | 09.11 ± 03.40 | 37.41 µM | 48.10% | 52.10% |
BZD38 | 03.23 ± 00.84 |  > 100 µM | 81.10% | 38.00% |
BZD46 | 83.90 ± 02.87 |  > 100 µM | 99.70% | 87.40% |
BZD55 | 07.11 ± 03.01 |  > 100 µM | 98.60% | 100% |
BZD56 | 93.93 ± 01.90 |  > 100 µM | 82.50% | 95.90% |
BZD58 | 45.12 ± 07.23 |  > 5 µM | 100% | 01.50% |
BZD59 | 91.16 ± 02.58 |  > 100 µM | 82.70% | 56.70% |
TCBZ | – |  > 50 µM | 81.00% | 01.60% |
ABZ (DD) | 99.01 ± 00.37 | – | – | – |